Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.61 |
| ▸ | CA2 | P00918 | 5/20 | 0.61 |
| ▸ | MMP1 | P03956 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.61 |
| ▸ | MMP13 | P45452 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 3/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706125 | 0.87 | SMN1; SMN2 (0.59) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL3065124 | 0.80 | ALDH1A1 (0.53) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL6927050 | 0.80 | CA1 (0.67) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL6241936 | 0.78 | CA1 (0.64) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL11314864 | 0.76 | CA2 (0.56) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL334232 | 0.76 | CA1 (0.61) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL2164002 | 0.76 | CA1 (0.61) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL250755 | 0.76 | GAA (0.64) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL2444492 | 0.76 | CA1 (0.61) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL2444494 | 0.76 | SMN1; SMN2 (0.64) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117535689-A | Method for synthesizing sulfonamide through decarbonylation of N, N-dimethylformamide and denitrification of sulfonyl hydrazide under electrochemical condition | 湘潭大学 | 2024-02-09 | — | — | CN | claimed |
| CN-117535689-A | Method for synthesizing sulfonamide through decarbonylation of N, N-dimethylformamide and denitrification of sulfonyl hydrazide under electrochemical condition | 湘潭大学 | 2024-02-09 | — | — | CN | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| EP-0650480-B1 | 1-ARYLSULPHONYL-3-PHENYL-1,4,5,6-TETRAHYDROPYRIDAZINES | ORTHO PHARMA CORP (US) | 2001-11-21 | — | — | EP | disclosed |
| US-5684151-A | PROGESTIN AGONISTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-11-04 | — | — | US | disclosed |
| EP-0650480-A1 | 1-ARYLSULPHONYL, ARYLCARBONYL AND 1-ARYLPHOSPHONYL-3-PHENYL-1,4,5,6-TETRAHYDROPYRIDAZINES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994001412-A1 | 1-ARYLSULPHONYL, ARYLCARBONYL AND 1-ARYLPHOSPHONYL-3-PHENYL-1,4,5,6-TETRAHYDROPYRIDAZINES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | CA1 2799/4885CA2 2357/4885MMP1 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.